Cas13 variants with minimal collateral effect are expected to be more competitive for in vivo RNA editing and future therapeutic applications, researchers claim.
Scientists from the Chinese Academy of Sciences (CAS) have allegedly developed a new “controllable, reversible and safer” gene-editing approach using CRISPR technology.
The system, named Cas13D-N2V8, showed a significant reduction in the number of off-target genes and no detectable collateral damage in cell lines and somatic cells, which indicated its future potential, according to a report published in South China Morning Post newspaper on Wednesday.
Researchers from the Chinese Academy of Sciences say their technology uses an enzyme that targets RNA and has more short-lived effects.
Comments are closed.